How this company measures up on the fundamentals that matter
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $166 against a fair value of $247, a 33% discount. Moderate competitive position. Fails ethical screen (Interest-bearing securities). Ranks better than 41% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-30 | HUNG PRISCILLA C | Director | 750 | $116,730 | |
| 2026-04-10 | HUNG PRISCILLA C | Director | 750 | $115,125 | |
| 2026-04-01 | VAN WAGENER BRIAN | Chief Financial Officer | 872 | — | |
| 2026-04-01 | KONDATH VIPIN | Officer | 2,603 | — | |
| 2026-04-01 | SCHWENGER THOMAS D | President | 2,043 | — | |
| 2026-04-01 | ZUPPAS ELENI NITSA A | President | 8,998 | — | |
| 2026-04-01 | FADDIS JONATHAN W | General Counsel | 8,726 | — | |
| 2026-03-05 | SCHWENGER THOMAS D | President | 1,000 | $200,000 | |
| 2026-02-27 | RITTER GORDON | Director | 297 | — | |
| 2026-02-27 | HUNG PRISCILLA C | Director | 262 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-01-31